课题基金 / 基金详情

I-Corps: Novel apatite/collagen scaffolds for bone repair

I-Corps: Novel apatite/collagen scaffolds for bone repair
I-Corps:用于骨修复的新型磷灰石/胶原支架
批准号:
1243455
负责人:
Mei Wei
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2013-12-31

项目摘要

项目成果

Mei Wei的其他基金

相似基金

相关文献

中文摘要
翻译
据报道,目前骨移植和骨替代材料的市场约为30亿美元,由于人口老龄化,市场逐年增长。 尽管对骨替代材料的需求很大,但目前许多可用的产品在一些关键领域都存在不足。有了以前的NSF奖和其他支持,PI?康涅狄格大学的研究小组开发了一种新型仿生骨支架,与目前可用的产品相比,该支架具有潜在的突破性性能:(1)上级机械性能,为初始手术操作提供必要的机械强度,并为增强新骨形成提供机械支持;(2)快速骨形成,这将显著缩短患者的康复时间;(3)与新骨长入速率相同的降解速率,导致用天然骨近乎完美的缺损修复;(4)简单、低成本且易于规模化大规模生产的制造工艺。如果成功,这一努力将提供从学术发现到商业化产品的新技术的转化。I-Corp对该提案的资助将使该团队能够更好地了解当前的骨替代品市场以及消费者、骨科和医疗器械公司的需求,从而最大限度地提高这种新型支架的潜在成功率。这样的理解将使团队能够制定一个与市场机会相匹配的计划,并指导从研发到强大产品的转变。
英文摘要
It is reported that the current market for bone graft and bone substitute materials is approximately $3 billion with continuous year to year growth due to the aging population. Despite the large demand in bone substitute materials, many currently available products fall short in some key areas. With the previous NSF award and other support, the PI?s research group at the University of Connecticut has developed a novel biomimetic bone scaffold with potentially breakthrough properties compared to currently-available products: (1) superior mechanical properties, providing the necessary mechanical strength for initial surgical handling and mechanical support for enhanced new bone formation; (2) rapid bone formation, which would significantly reduce the rehabilitation time for patients; (3) degradation rate that is identical to the new bone ingrowth rate, leading to near-perfect defect repair with natural bone; and;(4) a fabrication process that is simple, low cost, and easily scaled for mass production.If successful, this effort will provide the translation of a novel technology from academic discovery to a commercialized product. I-Corp funding of this proposal will enable the team to establish a better understanding of the current bone substitute market and the needs of consumers, orthopedic and medical device companies and importantly the patients thereby, maximizing the potential success of this novel scaffold. Such an understanding will allow the team to develop a plan that matches market opportunities, and guides the transformation from research and development to a robust product.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PFI:AIR - TT: Scale-up and Prototyping of Novel Scaffold Fabrication for Bone Regeneration
  • 批准号:
    2002879
  • 项目类别:
    Standard Grant
  • 资助金额:
    $13.41万
  • 财政年份:
    2020
  • 负责人:
    Mei Wei
  • 依托单位:
Symposium BM3, Biomaterials for Regenerative Medicine
  • 批准号:
    1638492
  • 项目类别:
    Standard Grant
  • 资助金额:
    $1.5万
  • 财政年份:
    2016
  • 负责人:
    Mei Wei
  • 依托单位:
PFI:AIR - TT: Scale-up and Prototyping of Novel Scaffold Fabrication for Bone Regeneration
  • 批准号:
    1639914
  • 项目类别:
    Standard Grant
  • 资助金额:
    $20.0万
  • 财政年份:
    2016
  • 负责人:
    Mei Wei
  • 依托单位:
PFI:AIR-TT: Prototyping bioabsorbable composites for bone-fixation applications involving low to medium loads
  • 批准号:
    1414274
  • 项目类别:
    Standard Grant
  • 资助金额:
    $20.0万
  • 财政年份:
    2014
  • 负责人:
    Mei Wei
  • 依托单位:
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: